

Jacques De Grève MD., PhD



Jacques De Grève MD., PhD

PROFESSOR

Oncology Specialist

Head of medical oncology and head of the laboratory of molecular oncology at the Hospital of Free University of Brussels (ULB). Chairman of the Belgian Society of Medical Oncology (BSMO), editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is professor of medical oncology and coordinator of a course molecular targets in cancer at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has 150 international scientific publications in high impact factor journals.

Full name: Jacques De Grève

Country: Belgium

Current Position:

Chairman of BSMO. Belgium.

Editor in chief of the Belgian Journal of Medical Oncology. Belgium.

Chairman of the Belgian Working party for the development of national cancer guidelines. Belgium.

Professor of medical oncology and coordinator of a course molecular targets in cancer at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. Belgium.

2013-present Head of the molecular oncology laboratory. ULB. Belgium.

1995-present Head of medical oncology. Hospital of ULB. Belgium.

Education:

1972-1979 Vrije school of medicine. The University of Brussels. Belgium.

Experience:

Chairman of BSMO. Belgium.

Editor in chief of the Belgian Journal of Medical Oncology. Belgium.

Chairman of the Belgian Working party for the development of national cancer guidelines. Belgium.

Professor of medical oncology and coordinator of a course molecular targets in cancer at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. Belgium.

2013-present Head of the molecular oncology laboratory. ULB. Belgium.

1995-present Head of medical oncology. Hospital of ULB. Belgium.

1984-1987 Member of Fogarty National Cancer Institute. National Institutes of Health (NIH).

Scientific publications

Number of publications as author or co-author: 150

Recent scientific publications:

Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer. Decoster L, Fontaine C, Vanacker L, Schallier D, De Grève J. *Breast J*. 2017 Dec 29. doi: 10.1111/tbj.12990.

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib. Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Grève J. *Oncotarget*. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer. Decoster L, Kenis C, Schallier D, Vansteenkiste J, Nackaerts K, Vanacker L, Vandewalle N, Flamaing J, Lobelle JP, Milisen K, De Grève J, Wildiers H. *Lung*. 2017 Oct;195(5):619-626. doi: 10.1007/s00408-017-0025-2. Epub 2017 Jun 20.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. *Oncotarget*. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study. Kenis C, Decoster L, Bastin J, Bode H, Van Puyvelde K, De Grève J, Conings G, Fagard K, Flamaing J, Milisen K, Lobelle JP, Wildiers H. *J Geriatr Oncol*. 2017 May;8(3):196-205. doi: 10.1016/j.jgo.2017.02.010. Epub 2017 Mar 18.